De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Enovis Toekomstige groei

Future criteriumcontroles 0/6

Enovis zal naar verwachting groeien in winst en omzet met respectievelijk 71.8% en 8.8% per jaar. De winst per aandeel zal naar verwachting groeien met 87.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 6.2% zijn.

Belangrijke informatie

71.8%

Groei van de winst

87.6%

Groei van de winst per aandeel

Medical Equipment winstgroei	17.5%
Inkomstengroei	8.7%
Toekomstig rendement op eigen vermogen	6.2%
Dekking van analisten	Good
Laatst bijgewerkt	03 Oct 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NYSE:ENOV - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	2,415	-5	N/A	N/A	8
12/31/2025	2,251	-36	124	383	11
12/31/2024	2,109	-109	31	278	11
6/28/2024	1,914	-107	-60	71	N/A
3/29/2024	1,817	-103	-37	91	N/A
12/31/2023	1,707	-54	13	135	N/A
9/29/2023	1,661	-112	-100	31	N/A
6/30/2023	1,627	-159	-106	19	N/A
3/31/2023	1,594	-23	-146	-34	N/A
12/31/2022	1,563	-39	-161	-56	N/A
9/30/2022	1,553	1	-23	76	N/A
7/1/2022	1,530	54	47	154	N/A
4/1/2022	1,491	-109	154	257	N/A
12/31/2021	1,426	-103	252	356	N/A
10/1/2021	1,855	-48	282	389	N/A
7/2/2021	2,301	-18	262	371	N/A
4/2/2021	2,565	21	222	330	N/A
12/31/2020	1,121	-75	187	302	N/A
10/2/2020	3,131	53	132	238	N/A
7/3/2020	3,172	39	102	214	N/A
4/3/2020	3,460	42	127	259	N/A
12/31/2019	3,327	8	6	131	N/A
9/27/2019	3,014	10	62	191	N/A
6/28/2019	2,692	21	94	203	N/A
3/29/2019	2,344	66	74	157	N/A
12/31/2018	2,193	108	157	226	N/A
9/28/2018	2,492	-115	133	205	N/A
6/29/2018	2,813	-84	87	154	N/A
3/30/2018	3,100	-92	N/A	176	N/A
12/31/2017	1,937	28	N/A	219	N/A
9/29/2017	3,239	154	N/A	260	N/A
6/30/2017	3,161	147	N/A	289	N/A
3/31/2017	3,043	151	N/A	272	N/A
12/31/2016	3,186	138	N/A	247	N/A
9/30/2016	3,435	144	N/A	254	N/A
7/1/2016	3,637	126	N/A	293	N/A
4/1/2016	3,933	138	N/A	321	N/A
12/31/2015	3,434	158	N/A	304	N/A
9/25/2015	4,112	204	N/A	336	N/A
6/26/2015	4,307	259	N/A	416	N/A
3/27/2015	4,481	397	N/A	451	N/A
12/31/2014	4,624	370	N/A	386	N/A
9/26/2014	4,589	322	N/A	377	N/A
6/27/2014	4,440	299	N/A	314	N/A
3/28/2014	4,314	160	N/A	309	N/A
12/31/2013	4,207	154	N/A	362	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ENOV de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ENOV de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ENOV de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ENOV ( 8.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van ENOV ( 8.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ENOV zal naar verwachting over 3 jaar laag zijn ( 6.2 %).

Enovis Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 7.1% to US$67.00

Consensus EPS estimates fall by 20%

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation Updates Earnings Guidance for the Year 2024

Price target increased by 8.6% to US$75.20

Enovis Corporation Provides Earnings Guidance for the Year 2024

Recent updates

Price target decreased by 7.1% to US$67.00

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis Corp Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Enovis Continues to Redefine Revision Knee Surgery with the Addition of Emowr Revision Knee

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Enovis Corporation Introduces Star Ankle, Now with E+ Polyethylene for Unmatched Durability

Consensus EPS estimates fall by 20%

Second quarter 2024 earnings: EPS misses analyst expectations

Enovis Corporation Narrows Revenue Guidance for the Year 2024

Enovis Corporation to Report Q2, 2024 Results on Aug 07, 2024

Enovis Languishing Despite Respectable Performance

Enovis Releases AltiVate Reverse Glenoid System, Widening Range of Patients Who May Be Treated with AltiVate Reverse

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis: Solid Growth, But Unstable Financial Footing

Enovis Corporation Updates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Enovis Corporation to Report Q1, 2024 Results on May 02, 2024

Enovis Corporation, Annual General Meeting, May 20, 2024

Price target increased by 8.6% to US$75.20

Full year 2023 earnings: EPS exceeds analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2024

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q4, 2023 Results on Feb 22, 2024

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Enovis Corporation Announces Leadership Transition Plan

Consensus EPS estimates fall by 87%

No longer forecast to breakeven

Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation to Report Q3, 2023 Results on Nov 07, 2023

Enovis Making Good Choices, But Not Seeing The Rewards

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Enovis Corporation signed an agreement to acquire Limacorporate S.p.A. from MIR Capital S.C.A., SICAR, EQT VII, EQT Partners AB and EQT VII for €800 million.

Is Enovis (NYSE:ENOV) A Risky Investment?

New major risk - Revenue and earnings growth

Enovis Corporation Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Enovis Corporation to Report Q2, 2023 Results on Aug 03, 2023

Price target increased by 8.0% to US$68.17

Enovis Corporation (NYSE:ENOV) acquired Novastep Inc. from Amplitude Surgical SA (ENXTPA:AMPLI).

Forecast breakeven date pushed back to 2024

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Independent Director notifies of intention to sell stock

Enovis Corporation Revises Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS misses analyst expectations

Enovis Corporation Q4 2022 Earnings Preview

Is Enovis (NYSE:ENOV) A Risky Investment?

Enovis Corporation to Report Q4, 2022 Results on Feb 23, 2023

Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Enovis Corporation Announces the Launch of the Dynaclip Delta and Dynaclip Quattro Bone Staples

Enovis Receives FDA Approval of Patient Specific Instrumentation for STAR Ankle

Enovis Corporation Announces Introduction of DynaNail Helix

High number of new directors

Third quarter 2022 earnings: EPS misses analyst expectations

Enovis Corporation Provides Earnings Guidance for the Year 2022

Enovis Corporation reports Q3 earnings beat; updates FY22 guidance

Is Enovis (NYSE:ENOV) A Risky Investment?

Now 21% undervalued after recent price drop

Enovis Corporation to Report Q3, 2022 Results on Nov 02, 2022

Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?

Price target decreased to US$67.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Enovis Launches ARVIS®, Only Augmented Reality Surgical Guidance System Designed Specifically to Improve Both Total Hip and Knee Replacement Surgery

Enovis launches augmented reality system ARVIS for use in hip, knee surgery